Use of dutasteride in carcinoma prostate

Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of urology Vol. 30; no. 1; pp. 123 - 124
Main Author Shrinivas, R
Format Journal Article
LanguageEnglish
Published Vellore Medknow Publications 01.01.2014
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer Medknow Publications
Subjects
Diagnosis
Drug therapy
Dutasteride
Health aspects
Medical research
Prostate cancer
Prostate-specific antigen
Radiation therapy
India
Online AccessGet full text

Cover

More Information
Summary:Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate carcinoma (PCa) with curative intent, being randomized 1:1 between placebo and dutasteride 0.5 mg once daily for 2 year. Another significant finding noted was the lower incidence of disease progression in the dutasteride group (17%; 25 of 146) compared with the placebo (34%; 49 of 144) in terms of incidence of PSA related progression like PSADT < 3 mo, Absolute high PSA and clinical progression such as positive biopsy, bone metastasis and the need for rescue therapy like anti-androgens or luteinizing hormone-releasing hormone therapy.
ISSN:0970-1591
1998-3824